missing translation for 'onlineSavingsMsg'
Learn More

LIMA1 Monoclonal Antibody (OTI7H8), TrueMAB™, OriGene

Mouse Monoclonal Antibody

Brand:  Origene Technologies TA808587S

Encompass_Preferred

 View more versions of this product

Product Code. 17530014

  • € 242.00 / 30µL

Please to purchase this item. Need a web account? Register with us today!

This item is not returnable. View return policy

Description

Description

LIMA1 Monoclonal antibody specifically detects LIMA1 in Human samples. It is validated for Immunohistochemistry (Paraffin), Western Blot
Specifications

Specifications

LIMA1
Monoclonal
1 mg/mL
PBS with 1% BSA, 50% glycerol and 0.02% sodium azide
Q7L2Z9
Mouse
Affinity chromatography
RUO
55166
-20° C, Avoid Freeze/Thaw Cycles
IgG1
Immunohistochemistry (Paraffin), Western Blot
OTI7H8
Unconjugated
CENPQ
1110021C24Rik; D15Ertd366e; Epithelial protein lost in neoplasm; epithelial protein lost in neoplasm beta; eplin; LIM domain and actin binding 1; LIM domain and actin-binding protein 1; LIMA1; mEPLIN; PP624; SREBP3; sterol regulatory element binding protein 3
Full length human recombinant protein of human CENPQ produced in E.coli.
30 μL
Primary
Human
Liquid
Product Suggestions

Product Suggestions

Videos
SDS
Documents

Documents

Certificates
Promotions

Promotions

Product Content Correction

The Fisher Scientific Encompass Program offers items which are not part of our distribution portfolio. These products typically do not have pictures or detailed descriptions. However, we are committed to improving your shopping experience. Please use the form below to provide feedback related to the content on this product.

Product Title

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.

Thank You! Your feedback has been submitted. Fisher Scientific is always working to improve our content for you. We appreciate your feedback.